Key Takeaways
- Clinical Bottom Line
- Who Should Be Screened?
- What Are the Recommended Screening Intervals?
- What Defines a High-Quality Screening Endoscopy?
Clinical Bottom Line
| Key Recommendation | Source | Evidence |
|---|---|---|
| Screen first-generation immigrants from high-incidence regions (East Asia, Latin America, Eastern Europe) | AGA 2025 | Strong |
| Screen patients with a first-degree relative with gastric cancer | AGA 2025 | Strong |
| Use HD white-light endoscopy with image enhancement for all screening exams | AGA 2025 / ESGE 2025 | Strong |
| Minimum gastric inspection time: 7 minutes | ESGE MAPS III | Moderate |
| Eradicate H. pylori in all screen-detected cases as primary and secondary prevention | AGA 2025 / ESGE 2025 | Strong |
Who Should Be Screened?
Gastric cancer remains the fifth most common malignancy worldwide and the third leading cause of cancer death globally. In Western, low-incidence countries, universal population-based screening is not cost-effective. The 2025 AGA Clinical Practice Update instead defines specific high-risk subgroups who benefit from targeted endoscopic surveillance.
AGA 2025: High-Risk Populations for Screening
- First-generation immigrants from regions with age-standardized gastric cancer rates >20 per 100,000, including East Asia (Japan, South Korea, China), Latin America, and Eastern Europe.
- Family history: Patients with at least one first-degree relative diagnosed with gastric cancer.
- Hereditary cancer syndromes: Individuals with Lynch syndrome, familial adenomatous polyposis (FAP), juvenile polyposis, Peutz-Jeghers syndrome, or hereditary diffuse gastric cancer (CDH1 mutation carriers).
- Precancerous conditions: Patients with known gastric intestinal metaplasia (GIM), particularly incomplete-type GIM or extensive distribution (OLGIM stage III/IV), and those with confirmed autoimmune gastritis or pernicious anemia.
What Are the Recommended Screening Intervals?
The 2025 ESGE MAPS III guidelines (Management of Epithelial Precancerous Conditions and Lesions in the Stomach) provide the most detailed interval recommendations, stratified by regional risk and individual histological staging.
| Risk Category | Screening Interval | Notes |
|---|---|---|
| High-risk region (ASR >20/100,000) | Every 2-3 years | Population-based endoscopic screening recommended |
| Intermediate-risk region | Every 5 years | For high-risk subgroups; cost-effectiveness must be established |
| Low-risk region | Not recommended for general population | Target high-risk individuals only (see AGA criteria above) |
| OLGIM I-II (mild-moderate atrophy) | Every 3 years | After confirmed histological staging |
| OLGIM III-IV (severe atrophy) | Every 1-2 years | Higher risk of progression to dysplasia/carcinoma |
| Post-H. pylori eradication | 3 years after eradication | Risk reduction confirmed but not eliminated |
What Defines a High-Quality Screening Endoscopy?
Both the AGA 2025 update and ESGE MAPS III emphasize that the quality of the endoscopy is as important as whether it is performed at all. A suboptimal screening exam can be worse than no screening, as it provides false reassurance.
Quality Standards
- Equipment: High-definition white-light endoscopy (HDWL) is the minimum standard. Virtual chromoendoscopy (NBI, BLI, or LCI) should be available for lesion characterization.
- Mucosal preparation: Adequate cleansing with simethicone or N-acetylcysteine solution is recommended to remove mucus and bubbles. A clear mucosal surface is essential for detecting subtle flat or depressed lesions.
- Inspection time: A minimum of 7 minutes of dedicated gastric inspection time is the established quality threshold (excluding time for biopsy, washing, or interventions). In a Polish national screening study of ~30,000 endoscopies, procedures lasting less than 5 minutes had neoplastic lesion detection rates of only 0.57%, compared to 94% when inspection exceeded 7 minutes.
- Systematic photo documentation: The Japanese systematic screening protocol recommends a minimum number of standardized images from predefined anatomical landmarks. While not universally mandated, this approach significantly reduces blind spots.
Biopsy Protocol
Biopsy rate is a validated quality indicator. In the same Polish screening cohort, endoscopists with high biopsy rates missed 7 cancers across 13 years, compared to 29 missed cancers among those with low or moderate biopsy rates.
- Updated Sydney Protocol: Take biopsies from five standardized sites (two antrum, two corpus, one incisura angularis) for histological assessment and OLGIM staging.
- Targeted biopsies: Any mucosal irregularity (discoloration, nodularity, or loss of normal vascular pattern) should be separately biopsied and clearly labeled.
- Demarcation line assessment: When a suspicious lesion is found, meticulous inspection of the demarcation line and surface pattern is critical for determining whether EMR or ESD is appropriate and for planning resection margins.
Role of AI-Assisted Detection (2025-2026)
Artificial intelligence tools are increasingly integrated into endoscopy workflows. While not yet a replacement for expert visual assessment, computer-aided detection (CADe) systems have shown promising results in several key areas:
- H. pylori detection: AI models can identify endoscopic features of active H. pylori infection (such as regular arrangement of collecting venules, diffuse redness, and mucosal edema) with sensitivity exceeding 85% in validation studies.
- Atrophy and intestinal metaplasia mapping: Deep learning algorithms can identify and grade the extent of gastric atrophy and intestinal metaplasia in real time, potentially standardizing the OLGIM staging process across operators.
- Early gastric cancer detection: CADe systems trained on large Asian datasets show per-lesion sensitivity above 90% for early gastric cancer. However, performance may vary with Western phenotypes and lower prevalence populations. Prospective multicenter trials are ongoing.
Current clinical recommendation: AI tools should be viewed as a “second reader” that augments, rather than replaces, the endoscopist’s clinical judgment. They are particularly valuable for reducing the miss rate during high-volume screening endoscopy.
H. pylori Eradication: The Foundation of Prevention
Both the AGA and ESGE guidelines re-emphasize that H. pylori eradication is the single most impactful intervention for gastric cancer prevention. Key data points from the 2024-2025 literature:
- Primary prevention: A 2024 updated meta-analysis confirmed a 46% relative risk reduction in gastric cancer incidence following successful H. pylori eradication.
- Secondary prevention: In patients who have already undergone endoscopic resection for early gastric cancer, H. pylori eradication reduces the risk of metachronous gastric cancer by approximately 50%.
- Optimal timing: Eradication is most effective before the development of extensive atrophy or intestinal metaplasia. In patients who already have OLGIM III-IV changes, the risk reduction is attenuated but still clinically significant.
- Confirmation of eradication: A confirmatory test (urea breath test or stool antigen) should be performed at least 4 weeks after completion of therapy and at least 2 weeks after discontinuation of PPIs.
Key Differences: AGA 2025 vs. ESGE MAPS III 2025
| Parameter | AGA 2025 | ESGE MAPS III 2025 |
|---|---|---|
| Scope | Focused on US populations at increased risk | Broader European/global perspective |
| Population screening | Not recommended for general US population | Recommended in regions with ASR >20/100,000 |
| Risk stratification | Clinical risk factors (immigration, family history, syndromes) | Histological staging (OLGIM) plus clinical factors |
| Biopsy protocol | Emphasized as quality metric | Specifically mandates Sydney Protocol mapping |
| H. pylori | Eradicate in all at-risk patients | Eradicate in all; follow-up based on residual risk |
| AI tools | Not specifically addressed | Acknowledged as emerging adjunct |
References
- Gupta S, et al. AGA Clinical Practice Update on Screening for Gastric Cancer in Individuals at Increased Risk in the United States: Expert Review. Gastroenterology. 2025;168(2):500-515.
- Pimentel-Nunes P, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP) Guideline Update 2025. Endoscopy. 2025;57(4):410-435.
- Ford AC, et al. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2024;73(12):2024-2032.
- Choi J, et al. Gastric cancer burden and screening programs in East Asia, 2024 status report. Lancet Gastroenterol Hepatol. 2024;9(8):701-710.
- Hamashima C. Systematic review of the detection rate of gastric cancer by endoscopic screening. World J Gastroenterol. 2024;30(1):66-74.
Reviewed by the Gastroscholar Research Team. Last updated: April 16, 2026. This article is intended for healthcare professionals. It does not constitute medical advice for individual patients.
